H. Lundbeck A/S: Completion of Randomisation in the DEEp SEA Phase III Trial

Overview of the Development Milestone

On 15 September 2026, H. Lundbeck A/S announced that the last patient has been randomised in the DEEp SEA (NCT06660394) Phase III study. The trial evaluates bexicaserin, an investigational molecule, for the treatment of seizures in children and adults with Dravet syndrome—a rare, severe childhood‑onset epilepsy classified as a developmental and epileptic encephalopathy (DEE).

Significance for the DEEp Programme

The completion of randomisation in DEEp SEA marks the final step in establishing the full participant cohort for the pivotal trial. The study is part of the broader DEEp Phase III programme, which also includes a parallel trial in a different geographic region. By securing enrolment, the company moves closer to collecting definitive efficacy, safety, and tolerability data needed for regulatory submissions.

Company Context

  • Sector: Health Care
  • Industry: Pharmaceuticals
  • Primary Exchange: OMX Nordic Exchange Copenhagen AS
  • Market Capitalisation: DKK 43,456,135,168
  • Recent Share Performance: Close price DKK 43.9 (2026‑09‑13); 52‑week high DKK 45; 52‑week low DKK 31.4
  • P/E Ratio: 11.79

H. Lundbeck focuses on research, development, production, and sales of treatments for psychiatric and neurological disorders across Europe, North America, and other markets.

Strategic Implications

The milestone supports Lundbeck’s objective to advance therapies for severe epilepsies, reinforcing its pipeline in neurological disorders. Successful outcomes from DEEp SEA could expand the company’s therapeutic portfolio and generate revenue in a high‑need patient segment.

Market Reaction

Shares of H. Lundbeck A/S traded at DKK 43.9 on 13 September 2026, reflecting investor confidence in the company’s clinical programme. The 52‑week trading range (31.4 – 45 DKK) indicates moderate volatility, typical for a pharmaceutical firm in the developmental stage.

Conclusion

The final randomisation in the DEEp SEA Phase III trial represents a critical operational achievement for H. Lundbeck A/S. It brings the company one step closer to generating the evidence required for regulatory approval of bexicaserin in Dravet syndrome, potentially opening new treatment avenues and strengthening Lundbeck’s position within the neurological therapeutics market.